Search Results - "Pollyea DA"

Lower-dose venetoclax (LoVe) based regimes in children with acute leukemia.

Authors: Purohit, Bhuvanesh Narayan Mohan, Vivek Capoor, Varun et al.

Source: Leukemia & Lymphoma. Nov2025, Vol. 66 Issue 11, p2128-2131. 4p.

Using cell-specific late-phase asthma mRNA biomarkers to repurpose drugs that concurrently reverse disease signatures across multiple immune cell-types.

Authors: Zhang, Mingming Kim, Young Woong Yang, Chen Xi et al.

Source: PLoS Computational Biology. 4/3/2026, Vol. 22 Issue 4, p1-19. 19p.

This result is not displayed to guests.
Login for full access.

L-2-hydroxyglutarate regulates centromere and heterochromatin conformation in the male germline.

Authors: Mayorek, Nina Schlossberg, Miriam Mansour, Yousef et al.

Source: PLoS Genetics. 7/10/2025, Vol. 21 Issue 7, p1-35. 35p.

SF3B1^K700E mutation in human embryonic stem cells causes aberrant expression of immune-related genes.

Authors: Dastpak, Mahtab Mimoso, Claudia A. Farshchian, Moein et al.

Source: PLoS ONE. 12/17/2025, Vol. 20 Issue 12, p1-20. 20p.

Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia.

Authors: Kamihara, Yusuke Kikuchi, Shohei Ishikawa, Nanako et al.

Source: PLoS ONE. 1/30/2026, Vol. 21 Issue 1, p1-14. 14p.

Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan.

Authors: Goshima, Yuki Saika, Tomoya Kado, Yuki et al.

Source: Leukemia & Lymphoma. May2026, p1-8. 8p. 4 Illustrations.

Hypotaurine promotes glioma cell invasion by hypermethylating the Wnt5a promoter.

Authors: Tian, Hong Chu, Xiaoli Guan, Qi et al.

Source: PLoS ONE. 5/15/2025, Vol. 20 Issue 5, p1-10. 10p.

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Authors: Zugasti, Ines Lopez-Guerra, Monica Castaño-Díez, Sandra et al.

Source: Experimental Hematology & Oncology. 4/26/2025, Vol. 14 Issue 1, p1-15. 15p.

The value of studying Programmed Death-1 +T cell immunoglobulin mucin 3 + exhausted T cells in patients of Acute Myeloid Leukemia.

Authors: Ghallab, Sarah A. Soliman, Ghada A.E.M. El Bedewy, Tamer A.E. et al.

Source: Egyptian Journal of Haematology. Jan-Mar2026, Vol. 51 Issue 1, p55-61. 7p.

NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia.

Authors: Sanchez II, John R. Liu, Chaomei Pawar, Vishakha et al.

Source: Leukemia & Lymphoma. Jan2026, Vol. 67 Issue 1, p97-107. 11p.

Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.

Authors: Soua, Amel Gilhodes, Julia Iat, Alexandre et al.

Source: European Journal of Haematology. Dec2024, Vol. 113 Issue 6, p751-757. 7p.

Targeting LAPTM5 enhances AML sensitivity to cytarabine through autophagy inhibition.

Authors: Zeng Y He C Chen H et al.

Source: Cell death & disease [Cell Death Dis] 2026 Mar 30; Vol. 17 (1). Date of Electronic Publication: 2026 Mar 30.

Publication Type: Journal Article

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE

Immunophenotypic changes following menin inhibition in acute myeloid leukemia.

Authors: Loghavi S Farhat A Jamison TJ et al.

Source: Leukemia [Leukemia] 2026 Jun; Vol. 40 (6), pp. 1142-1150. Date of Electronic Publication: 2026 Mar 11.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Cellular hierarchy for understanding heterogeneity of acute myeloid leukaemia with t(8;21)/RUNX1‐RUNX1T1.

Authors: Wu, Yibo Yuan, Xiaolin Lai, Xiaoyu et al.

Source: Clinical & Translational Immunology. 2025, Vol. 14 Issue 7, p1-15. 15p.

This result is not displayed to guests.
Login for full access.

EWSR1 as a candidate prognostic indicator in acute myeloid leukemia.

Authors: Qian, Lihui Zhang, Pei Chen, Ting et al.

Source: Hematology. Dec2025, Vol. 30 Issue 1, p1-15. 15p.

METTL7A is a potential biomarker for the diagnosis and prognosis of acute myeloid leukemia.

Authors: Xie, ZhiBin Tan, YuanYuan Zhang, TingTing et al.

Source: Hematology. Dec2025, Vol. 30 Issue 1, p1-12. 12p.

Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.

Authors: Park, Hyunkyung Lee, Je-Hwan Lee, Jung-Hee et al.

Source: Leukemia & Lymphoma. Dec2025, Vol. 66 Issue 12, p2249-2259. 11p.

Venetoclax promotes acute myeloid leukemia cells apoptosis by decreasing ac4C modification and mRNA expression of IMP3 through downregulating NAT10.

Authors: Lu, Lina Liang, Jiayi Wang, Luting et al.

Source: Leukemia & Lymphoma. Dec2025, Vol. 66 Issue 12, p2285-2295. 11p.